Sarepta Therapeutics said Monday that a second-generation medicine for patients with a certain type of Duchenne muscular dystrophy showed improved performance in laboratory tests over the biotech’s marketed treatment.
In a small clinical trial, a monthly infusion of the new Sarepta drug, called SRP-5051, produced eight times more of the muscle protein dystrophin compared to weekly infusions of Exondys 51, the company’s existing product.
Signs of kidney toxicity — a particular area of concern for SRP-5051 — were not observed in any of the treated patients. However, two patients reported low levels of magnesium in their bloodstream that were considered severe adverse events.
About the Author Reprints
